Witness Testimony

Alan Cassels testified as a pharmaceutical policy researcher with expertise in drug evaluation and industry marketing practices. He stated that the pharmaceutical industry has a documented history of influencing research, regulatory decisions, and public messaging, and he expressed concern that similar patterns were present during the COVID-19 vaccine rollout. He emphasized the importance of independent data review, transparency in clinical trial reporting, and scrutiny of conflicts of interest between industry, regulators, and academic institutions.
Cassels highlighted issues related to the communication of vaccine efficacy, particularly the distinction between relative and absolute risk reduction, and the limitations of post-marketing adverse event surveillance systems. He testified that emergency authorization processes reduced standard timelines for long-term safety evaluation and that full access to raw clinical trial data was limited. He argued that regulatory agencies should require greater transparency and independent analysis before approving widespread medical interventions.
He further discussed the role of media and public health messaging in shaping public perception, stating that balanced discussion of benefits and risks is essential for informed consent. Cassels advocated for stronger firewalls between pharmaceutical funding and policy-making bodies, enhanced disclosure of financial relationships, and improved public access to primary data to ensure evidence-based decision-making in future health emergencies.